These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20886180)

  • 1. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?
    Giannarelli C; Zafar MU; Badimon JJ
    Thromb Haemost; 2010 Nov; 104(5):949-54. PubMed ID: 20886180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Terutroban and endothelial TP receptors in atherogenesis].
    Verbeuren TJ
    Med Sci (Paris); 2006 Apr; 22(4):437-43. PubMed ID: 16597416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy: targeting the TxA2 pathway.
    Fontana P; Zufferey A; Daali Y; Reny JL
    J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention.
    Chamorro A
    Cerebrovasc Dis; 2009; 27 Suppl 3():20-7. PubMed ID: 19439937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane receptors antagonists and/or synthase inhibitors.
    Davì G; Santilli F; Vazzana N
    Handb Exp Pharmacol; 2012; (210):261-86. PubMed ID: 22918735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thromboxane/endoperoxide receptor (TP): the common villain.
    Félétou M; Vanhoutte PM; Verbeuren TJ
    J Cardiovasc Pharmacol; 2010 Apr; 55(4):317-32. PubMed ID: 20422736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of nonprostanoid trimetoquinol analogs with thromboxane A2/prostaglandin H2 receptors in human platelets, rat vascular endothelial cells and rat vascular smooth muscle cells.
    Shin Y; Romstedt KJ; Miller DD; Feller DR
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1017-23. PubMed ID: 7903383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y
    Fu J; Zhu X; Wang W; Lu H; Zhang Z; Liu T; Xu H; Fu H; Ma S; Luo Y
    Phytomedicine; 2017 Dec; 36():273-282. PubMed ID: 29157825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common binding site for primary prostanoids in vascular smooth muscles: a definitive discrimination of the binding for thromboxane A2/prostaglandin H2 receptor agonist from its antagonist.
    Hanasaki K; Arita H
    Biochim Biophys Acta; 1989 Sep; 1013(1):28-35. PubMed ID: 2528990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
    Halushka PV; Mais DE; Saussy DL
    Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L; Fitzgerald DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative thromboxane A2/prostaglandin H2 receptor activity predicts early graft thrombosis.
    Brothers TE; Robison JG; Elliott BM; Boggs JM
    J Vasc Surg; 1998 Feb; 27(2):317-25; discussion 326-8. PubMed ID: 9510286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboxane A2 induces blood flow recovery via platelet adhesion to ischaemic regions.
    Amano H; Ito Y; Eshima K; Kato S; Ogawa F; Hosono K; Oba K; Tamaki H; Sakagami H; Shibuya M; Narumiya S; Majima M
    Cardiovasc Res; 2015 Sep; 107(4):509-21. PubMed ID: 25935870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.